The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibody Share News (FAB)

Share Price Information for Fusion Antibody (FAB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.35
Bid: 3.30
Ask: 3.40
Change: 0.00 (0.00%)
Spread: 0.10 (3.03%)
Open: 3.35
High: 3.35
Low: 3.35
Prev. Close: 3.35
FAB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EXECUTIVE CHANGES: Cohort co-founder out; Nuformix co-founder back

Thu, 28th Jul 2022 16:14

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Thursday and not separately reported by Alliance News:

----------

Cohort PLC - Reading-based defence and security markets-focussed technology - Stanley Carter will depart as non-executive director at Cohort's annual general meeting on September 27. Carter co-founded Cohort in 2006, serving first as chief executive and then as co-chair in 2009, before stepping down to non-executive director in 2015. Nick Prest, who co-founded Cohort with Carter, remains chair. Carter remains a 22% shareholder.

----------

Nuformix PLC - London-based pharmaceutical firm targeting fibrosis and oncology via drug repurposing - Dan Gooding rejoins company as executive director. Gooding was a co-founder of Nuformix and its CEO until June 2020. He has been acting as a consultant to the company since March. Also promotes Non-Executive Director Julian Gilbert to non-executive chair. The board now will have three members, including also Non-Executive Director Maddy Kennedy.

----------

Fusion Antibodies PLC - Belfast-based pre-clinical antibody discovery, engineering and supply for therapeutic drug and diagnostic applications - Hires Adrian Kinkaid as CEO, starting August 15. Says Kinkaid has 25 years experience in life science and biotherapeutics industries. He joins from Vortex Liquid Biopsy Solutions Ltd and Vortex Biosciences Inc, where he was CEO.

----------

ECSC Group PLC - Bradford, West Yorkshire-based cyber security services provider - Hires Matthew Briggs as CEO, starting immediately, while Ian Mann will move to executive chair from CEO. Briggs was chief commercial officer for motor breakdown cover provider RAC Ltd, a divisional managing director at Aviva PLC, and CEO of Capita Insurance, part of Capita PLC.

----------

Alien Metals Ltd - mineral exploration in Australia, Mexico and Greenland - Hires Rod McIllree as executive chair. As a result, Bill Brodie Good steps down immediately as a company director but remains as non-board CEO, focused on operations, particularly at the Hancock iron ore project in Western Australia. Dan Smith steps down as chair but remains as a non-executive director. McIllree was most recently executive chair of fellow AIM listing Bluejay Mining PLC.

----------

Sportech PLC - London-based betting technology - Chief Financial Officer Nicola Rowlands will leave Sportech at the end of September to become deputy CFO of an unnamed marketing services firm. Sportech says it will appoint a replacement "in due course", though also says it is "considering its appropriate composition going forward". Rowlands will remain in place through the release of interim results in September, Sportech says.

----------

Wincanton PLC - Wiltshire, England-based logistics - Hires Tom Hinton as CFO and board member, starting August 15. Most recently, Hinton was CFO at WE Soda Ltd, a mining and chemicals firm.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
30 Apr 2024 19:54

EARNINGS AND TRADING: Software Circle & Beximco report higher revenue

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
15 Apr 2024 13:29

Fusion Antibodies inks commercial contract for OptiPhage library

(Alliance News) - Fusion Antibodies PLC on Monday said that it has signed a commercial contract to develop an OptiPhage library for a non-human antibody species.

Read more
27 Feb 2024 14:18

TRADING UPDATES: Sondrel wins USD23 million contract

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
27 Feb 2024 13:15

Fusion Antibodies gets first order under new services agreement

(Sharecast News) - Fusion Antibodies announced the receipt of its first purchase order under a master services agreement on Tuesday, which it agreed with a prominent diagnostics company on 14 February.

Read more
14 Feb 2024 12:52

Fusion Antibodies raises £1.38m as it seeks new customers

(Sharecast News) - Pre-clinical antibody specialist Fusion Antibodies announced a conditional fundraising of £1.38m before expenses on Wednesday, to help it target mo re industry conferences and customers and generate further supporting data.

Read more
14 Feb 2024 11:27

IN BRIEF: Fusion Antibodies raises GBP1.4 million via placing

Fusion Antibodies PLC - Belfast-based contract researcher, which provides discovery, design and optimisation services for therapeutic antibodies to the healthcare market - Conditionally raises GBP1.4 million before expenses via placing of 34.4 million shares at 4 pence each. The issue price represents a discount of 5.9% to Fusion's closing mid-market share price on Tuesday. Further, it intends to issue 1.5 million new shares to certain directors in lieu of or in satisfaction of salary and fees due to them and which shall be issued immediately following publication of its announcement. Also intends to grant a total of up to 3.8 million new share options to staff and senior management.

Read more
6 Feb 2024 11:48

Fusion Antibodies strikes follow-on research and development project

(Alliance News) - Fusion Antibodies PLC on Tuesday said it has won a follow-on project under a collaborative research and development agreement with an unnamed "US-based biotechnology company".

Read more
6 Feb 2024 10:05

AIM WINNERS & LOSERS: Beeks Financial Cloud is ahead of expectations

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
1 Feb 2024 16:27

Fusion Antibodies confirms £0.28m tax credit

(Sharecast News) - Preclinical antibody discovery specialist Fusion Antibodies announced the successful receipt of a research and development tax credit from HMRC on Thursday.

Read more
1 Feb 2024 12:00

Fusion Antibodies gets tax credit from UK HMRC for OptiMAL platform

(Alliance News) - Fusion Antibodies PLC on Thursday announced the receipt of a research & development tax credit from UK HM Revenue & Customs for work performed on the development of its OptiMAL platform and other projects in bioinformatics.

Read more
4 Dec 2023 16:56

LONDON MARKET CLOSE: FTSE 100 slips as miners hold down index

(Alliance News) - Stock prices in London closed lower on Monday, with miners and oil firms holding down the FTSE 100 index.

Read more
4 Dec 2023 12:01

Fusion Antibodies revenue falls, losses widen in first half

(Sharecast News) - Contract research organisation Fusion Antibodies reported first-half revenue of £0.54m on Monday, down from £1.9m a year earlier.

Read more
4 Dec 2023 10:23

AIM WINNERS & LOSERS: Cornerstone FS to beat 2023 expectations

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
4 Dec 2023 10:22

Fusion Antibodies shares fall with revenue despite "positive" outlook

(Alliance News) - Fusion Antibodies PLC on Monday reported a widened loss and reduced revenue for its latest half year, but said its growth prospects are "increasingly positive".

Read more
28 Nov 2023 12:09

Fusion Antibodies shares up on deal with US National Cancer Institute

(Alliance News) - Fusion Antibodies PLC on Tuesday said it has signed a collaboration agreement with the US National Cancer Institute to use its OptiMAL product to discover novel antibodies to treat certain targets.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.